

Novartis Pharmaceuticals Canada Inc. is proud to announce a new indication for **XOLAIR**®

Now available for the treatment of severe chronic
rhinosinusitis with nasal polyps (CRSwNP)¹

For adult patients with severe CRSwNP inadequately
controlled by intranasal corticosteroids alone¹

Think **XOLAIR**®

as add-on maintenance treatment with
intranasal corticosteroids

Explore the breadth of indications for **XOLAIR**®

XOLAIR® (omalizumab) is indicated for:¹



NEW

Chronic rhinosinusitis with nasal polyps (CRSwNP)

Add-on maintenance treatment with intranasal corticosteroids in adult patients with severe CRSwNP inadequately controlled by intranasal corticosteroids alone.



Allergic asthma

Adult and pediatric patients (6 years of age and above) with moderate to severe persistent asthma who have a positive skin test or *in vitro* reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.



Chronic idiopathic urticaria (CIU)

The treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria (CIU) who remain symptomatic despite H1 antihistamine treatment.

View our latest **Product Monograph** to learn more about
the new indication

Download



Consider **XOLAIR® for your
patients with CRSwNP**

Consult the Product Monograph at www.novartis.ca/XolairMonograph for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, conditions of clinical use, and dosage and administration information. The Product Monograph is also available by calling 1-800-363-8883.

Reference:

1. XOLAIR® Product Monograph. Novartis Pharmaceuticals Canada Inc., July 19, 2021.

* Comparative clinical significance unknown.

By clicking unsubscribe, you will stop receiving electronic communications on products, programs, and other matters from Novartis Pharmaceuticals Canada Inc.

Opting out will not apply to Novartis communications consisting into (1) informational emails including emails sent in the ordinary course of business by Novartis personnel (2) specialized/dedicated content (3) channels you may have subscribed to and/or (4) safety notifications.

Unsubscribe



NOVARTIS

Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval (Quebec) H9S 1A9
www.novartis.ca
Tel: 514-631-6775 Fax: 514-631-1867
Medical Information Tel: 1-800-363-8883

© 2021 Novartis Pharmaceuticals Canada Inc.
All rights reserved.
® XOLAIR is a registered trademark.
September/2021 – 141086E